Prognostic Utility of PET in Prostate Cancer. - Wikidata - awgldk - TriplyDB

Prognostic Utility of PET in Prostate Cancer.

Prognostic Utility of PET in Prostate Cancer.

http://www.wikidata.org/entity/Q35244433

about

PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Is There Use for FDG-PET in Prostate Cancer?

P2860

Q37390670-D326A4D4-2E24-4AA8-A443-7D748969D89C Q39003083-16569CB9-DE76-4D9E-8656-D2407E1B01C7

P2860

Prognostic Utility of PET in Prostate Cancer.

http://www.wikidata.org/entity/Q35244433

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Prognostic Utility of PET in Prostate Cancer.

@ast

Prognostic Utility of PET in Prostate Cancer.

@en

type

label

Prognostic Utility of PET in Prostate Cancer.

@ast

Prognostic Utility of PET in Prostate Cancer.

@en

prefLabel

Prognostic Utility of PET in Prostate Cancer.

@ast

Prognostic Utility of PET in Prostate Cancer.

@en

P1433

Q35244433-290429FB-6825-4CF8-844C-0F13B898B109

P1476

Q35244433-73E519DB-30F8-4ADD-A7B0-B4B7BE8938FA

P2093

Q35244433-4D102D07-27D5-4140-A44D-D830E036CAE2

P2860

Q35244433-027A0C17-1CD2-431C-B8F6-A457F3BC2357

Q35244433-07582850-60A6-44A3-B2B8-F52AF2488275

Q35244433-0ED93FB2-9A51-41A3-A5B0-4D84471F5E5C

Q35244433-0F4B2B68-B31B-4499-B312-FE45E02911C9

Q35244433-15714A9A-3345-4AB4-B718-F87F908CB3A6

Q35244433-19B11CB3-A0B3-4364-A0C1-3D14E41743A9

Q35244433-1B4E7979-FC63-4A5D-AEE1-273384ACF331

Q35244433-1B5B8297-387E-44B0-BF43-15EF91E39865

Q35244433-1BA17C91-A4CA-4FF2-B195-F6A095FBFEA4

Q35244433-1D9C11EB-BB83-4335-B7B7-7A2BDAB5621A

P304

Q35244433-E6714E5B-F514-433C-87E2-85CBC6D88E83

P31

Q35244433-FE9B59D1-93FE-48DC-B9D9-5C8594465A95

P356

Q35244433-7EF29E29-E999-4DFC-8955-4FB62E9EC3B6

P433

Q35244433-744A885B-9017-450C-AE05-736988DAE10D

P478

Q35244433-BE1301A7-6B5A-4520-AE38-F19C3083AD11

P577

Q35244433-15BA2B43-F790-4275-A67D-EA0BEAD2D737

P698

Q35244433-E587AC7F-02A8-4067-9BA1-4361C00B19CD

P932

Q35244433-2A8D98B5-4FA8-4C0E-9621-2CD5D54005CB

P356

J.CPET.2014.12.007

P1433

P1476

Prognostic Utility of PET in Prostate Cancer.

@en

P2093

Hossein Jadvar

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging of prostate carcinoma

Treatment of recurrent prostate cancer following radical prostatectomy: the radiation-oncologists point of view

Current state of castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.

P304

255-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CPET.2014.12.007

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25829090

http://www.w3.org/2001/XMLSchema#string

P932

4382583

http://www.w3.org/2001/XMLSchema#string